Askbio

ReCode Therapeutics partnering with Bayer's AskBio on single vector gene-editing platform

09-Jan-2023 By Jane Byrne

The collaboration will combine ReCode’s delivery technology with AskBio’s gene editing and DNA cargoes to develop gene correction therapies for liver and lung diseases.

AskBio subsidiary readies to start clinical trials for Huntington’s Disease gene therapy

25-Aug-2022 By Rachel Arthur

BrainVectis, a subsidiary of AskBio, has received clearance from the French authorities to start a Phase 1-2 clinical trial for its novel Huntington’s Disease gene therapy, BV-101.

Bayer acquires Asklepios BioPharmaceutical in deal worth up to $4bn

26-Oct-2020 By Rachel Arthur

Bayer will broaden its innovation base in cell and gene therapy with the acquisition of Asklepios BioPharmaceutical (AskBio): a US biotech working in gene therapies across different therapeutic areas.

AskBio buys BrainVectis for early-stage gene therapies

27-Apr-2020 By Ben Hargreaves

AskBio acquires gene therapy biotech working on treatments for neurodegenerative disorders.

Hired and Retired: Management moves in a time of crisis

08-Apr-2020 By Ben Hargreaves

As the pandemic continues to rumble on, biopharma companies have been reshuffling the pack on their executive boards.

Editas touts manufacturing benefits of teaming up with AskBio

20-Nov-2019 By Nick Taylor

Editas Medicine points to AskBio’s ‘excellent manufacturing facility’ and associated expertise to explain benefits of recent partnership.